publication date: May. 12, 2017

How one bad sentence in the Cures Act blocked FDA’s cancer center from receiving $75 million

By Matthew Bin Han Ong

The FDA Oncology Center of Excellence occupied a special place in the Obama White House moonshot program.

Amid the moonshot’s big goals, the FDA center was concrete, manageable, and modestly priced, a reorganization that promised to revolutionize the agency’s handling of everything cancer.

How is the place faring today?

Not well, by anyone’s standards.

The long-awaited center that was designed to focus the entire FDA oncology portfolio in one administrative unit staffed by cancer experts is caught up in a classic Catch-22 impasse. The money for the center exists. It has even been appropriated. But because of what looks like a language snafu by Congressional authorizing committees, the money is, for the foreseeable future, stuck at NIH.

Congress had the capacity to fix the problem in the recently passed FY2017 spending bill, but, alas, didn’t. In principle, an interagency agreement can be used to pry the money out of NIH, but that path comes with unexpected twists.   

When Congress passed the 21st Century Cures Act in December 2016, authorizers set aside $1.8 billion for cancer research via NIH and NCI over seven years. Of that … Continue reading How one bad sentence in the Cures Act blocked FDA’s cancer center from receiving $75 million

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.